This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Sacubitril

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril].
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril].
-
Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.[2] Sacubitrilat inhibits the enzyme neprilysin,[3] which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure–lowering peptides that work mainly by reducing blood volume.[4]
+
Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.<ref name="a2">Solomon SD. [https://esc365.escardio.org/home "HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline".] Boston. p. 48. Retrieved 2012-01-26</ref> Sacubitrilat inhibits the enzyme neprilysin,<ref name="a3">PMID:28438180</ref> which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure–lowering peptides that work mainly by reducing blood volume.<ref name="a4">PMID:28438180</ref>
<scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH Sacubitrilat</scene> ([[5jmy]]).
<scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH Sacubitrilat</scene> ([[5jmy]]).

Revision as of 10:00, 16 October 2023

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. ↑ Solomon SD. "HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline". Boston. p. 48. Retrieved 2012-01-26
  2. ↑ Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97. PMID:28438180 doi:10.1186/s13045-017-0467-2
  3. ↑ Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97. PMID:28438180 doi:10.1186/s13045-017-0467-2

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel

Retrieved from "http://52.214.119.220/wiki/index.php/Sacubitril"
Personal tools